About Eliem Therapeutics
Eliem Therapeutics is a company based in Boston (United States) founded in 2018 by Valerie Morisset and Andrew Levin. It operates as a B2B. Eliem Therapeutics has raised $171.3 million across 5 funding rounds from investors including RA Capital, ICG and LifeArc. The company has 30 employees as of December 31, 2022. Eliem Therapeutics has completed 1 acquisition, including Tenet Medicines. Eliem Therapeutics offers products and services including Budoprutug. Eliem Therapeutics operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Ethypharm, Zogenix and Heron Therapeutics, among others.
- Headquarter Boston, United States
- Employees 30 as on 31 Dec, 2022
- Founders Valerie Morisset, Andrew Levin
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eliem Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$171.3 M (USD)
in 5 rounds
-
Latest Funding Round
$60 M (USD), Series C
May 01, 2021
-
Investors
RA Capital
& 5 more
-
Employee Count
30
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eliem Therapeutics
Eliem Therapeutics offers a comprehensive portfolio of products and services, including Budoprutug.
Anti-CD19 antibody to deplete B cells and reduce autoantibodies.
People of Eliem Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Eliem Therapeutics
Eliem Therapeutics has successfully raised a total of $171.3M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $60 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eliem Therapeutics
Eliem Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, ICG and LifeArc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
ICG is recognized as a global alternative asset manager.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Locked | Locked | Locked |
Investor details for Eliem Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eliem Therapeutics
Eliem Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tenet Medicines.
Investment portfolio details for Eliem Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for autoimmune-driven inflammatory diseases are developed.
|
Locked | Locked | 2023 | Locked |
Complete acquisition details for Eliem Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Eliem Therapeutics
Detailed financials for Eliem Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eliem Therapeutics Comparisons
Peer comparison for Eliem Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eliem Therapeutics
Eliem Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Ethypharm, Zogenix and Heron Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
Detailed competitors of Eliem Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eliem Therapeutics
Complete news archive for Eliem Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eliem Therapeutics
Eliem Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Eliem Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Eliem Therapeutics is a funded company, having raised a total of $171.3M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Eliem Therapeutics is 30.
Eliem Therapeutics is a clinical-stage biopharmaceutical company focused on creating therapeutics for autoimmune-driven inflammatory diseases. They advance treatments like budoprutug, an anti-CD19 antibody that depletes B cells to reduce autoantibodies. Operating from locations in the US and UK, they conduct clinical trials for conditions such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, collaborating with experts in biotechnology.
Eliem Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Eliem Therapeutics offers Budoprutug.
Eliem Therapeutics has made 1 acquisition, including Tenet Medicines.
Eliem Therapeutics has 6 investors. Key investors include RA Capital, ICG, LifeArc, Access Biotechnology, and Samlyn Capital.